GSK plc
General ticker "GLAXF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $101.0B (TTM average)
GSK plc does not follow the US Stock Market performance with the rate: -4.2%.
Estimated limits based on current volatility of 1.2%: low 24.18$, high 24.77$
Factors to consider:
- Earnings expected soon, date: 2026-10-28 bmo
- Company pays dividends (semi-annually): last record date 2026-08-14, amount 0.23$ (Y1.88%)
- Total employees count: 94066 (+35.7%) as of 2025
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [18.67$, 29.54$]
- 2026-12-31 to 2027-12-31 estimated range: [21.39$, 32.98$]
Financial Metrics affecting the GLAXF estimates:
- Positive: with PPE of 10.3 at the end of fiscal year the price was neutral
- Positive: 8.77 < Operating cash flow per share per price, % of 10.20
- Positive: 15.80 < Operating profit margin, % of 21.95
- Positive: 7.19 < Return on assets ratio (scaled to [-100,100]) of 8.55
- Positive: -11.23 < Investing cash flow per share per price, % of -8.17
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
- Negative: Industry operating cash flow per share per price (median), % of 5.61 <= 7.15
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
Short-term GLAXF quotes
Long-term GLAXF plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | £31,376.00MM | £32,661.71MM |
| Operating Expenses | £27,355.00MM | £25,493.87MM |
| Operating Income | £4,021.00MM | £7,167.84MM |
| Non-Operating Income | £-544.00MM | £231.96MM |
| Interest Expense | £640.00MM | £700.89MM |
| R&D Expense | £6,401.00MM | £7,506.78MM |
| Income(Loss) | £3,477.00MM | £7,399.80MM |
| Taxes | £526.00MM | £1,111.82MM |
| Net Income(Loss)* | £2,575.00MM | £5,715.07MM |
| Stockholders Equity | £13,671.00MM | £16,374.35MM |
| Inventory | £5,669.00MM | £5,923.04MM |
| Assets | £59,463.00MM | £61,108.10MM |
| Operating Cash Flow | £6,554.00MM | £7,301.82MM |
| Capital expenditure | £2,982.00MM | £1,347.78MM |
| Investing Cash Flow | £-1,229.00MM | £-5,850.05MM |
| Financing Cash Flow | £-4,726.00MM | £-1,628.74MM |
| Earnings Per Share** | £0.63 | £1.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.